Senotherapeutics mitigate the root drivers of age- and obesity-related metabolic disease

A growing body of evidence implicates cellular senescence-when cells age and permanently stop dividing-as an important contributor to metabolic dysfunction that can lead to obesity, type 2 diabetes, and metabolic syndrome.